<SEC-DOCUMENT>0001683168-19-001306.txt : 20190501
<SEC-HEADER>0001683168-19-001306.hdr.sgml : 20190501
<ACCEPTANCE-DATETIME>20190501161511
ACCESSION NUMBER:		0001683168-19-001306
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190429
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190501
DATE AS OF CHANGE:		20190501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		19787708

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">April 29, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">(Date
of the earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Simulations
Plus, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">California</FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">001-32046</FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">95-4595609</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(Commission File Number)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">42505 10<SUP>th</SUP> Street West,
Lancaster, California 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">661-723-7723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Registrant's
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). &#9;Emerging Growth Company [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Appointment of Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2019, the Nominating Committee
of Simulation Plus, Inc.&rsquo;s (the &ldquo;Company&rdquo;) Board of Directors (the &ldquo;Board&rdquo;) nominated Dr. Lisa LaVange
to the Board. The Board unanimously voted to appoint Dr. LaVange to join the Board effective May 1, 2019. She will hold this position
until the next annual meeting of the Company&rsquo;s shareholders or until her successor is elected and qualified, subject to her
earlier resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. LaVange was chosen for her extensive
expertise with biostatistics and experience with academia, commercial organizations, and government regulators, including a senior
position at the U.S. Food and Drug Administration (FDA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. LaVange is expected to be named as
Chairman of the Compensation Committee and a member of the Audit Committee as well as the Nominating Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no arrangement or understanding
between Dr. LaVange and any other person pursuant to which Dr. LaVange was selected as a director of the Company. Other than the
Company&rsquo;s formal plan for compensating its directors for their services, whereby each independent director receives $2,500
per meeting of the Board attended, annual stock grants valuing $49,000, and an annual stipend of $11,000, there are no plans, contracts
or arrangements or amendments to any plans, contracts or arrangements entered into with Dr. LaVange in connection with her election
to the Board, nor are there any grants or awards made to Dr. LaVange in connection therewith. Dr. LaVange is not a participant
in, nor is she to be a participant in, any related-person transaction or proposed related-person transaction required to be disclosed
by Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Resignation of Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2019, Dr. Thaddeus H. Grasela,
resigned as a director from the Company, effective as of April 29, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 7.01</B></TD><TD STYLE="text-align: justify"><B>Regulation FD Disclosure</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2019, the Company announced the
appointment of Dr. LaVange to the Board. A copy of the press release issued by the Company announcing Dr. LaVange&rsquo;s appointment
is attached hereto as Exhibit 99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth under Item 7.01
of this Current Report on Form 8-K (&ldquo;Current Report&rdquo;), including Exhibit 99.1 attached hereto, is being furnished and
shall not be deemed to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
&quot;Exchange Act&quot;), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report
shall not be deemed an admission as to the materiality of any information in this report on Current Report that is required to
be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report, including the disclosures
set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein,
the terms &quot;anticipates,&quot; &quot;expects,&quot; &quot;estimates,&quot; &quot;believes&quot; and similar expressions, as
they relate to us or our management, are intended to identify such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements in this Current
Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the &quot;Commission&quot;),
reports to the shareholders of Simulations Plus, Inc., a California corporation (the &quot;Company&quot; or &quot;us,&quot; &quot;our&quot;
or &quot;we&quot;) and other publicly available statements issued or released by us involve known and unknown risks, uncertainties
and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the
future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such
future results are based upon management's best estimates based upon current conditions and the most recent results of operations.
These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission,
each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual
results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in">99.1</TD><TD><A HREF="simulations_ex9901.htm">Press release issued on May 1, 2019.</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>SIMULATIONS PLUS, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">May 1, 2019</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%"><I>/s/ Shawn O&rsquo;Connor</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Shawn O&rsquo;Connor<BR>Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 58px; width: 280px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACT</B>:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt"><U>Simulations Plus Investor Relations</U></FONT></TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt"><U>Hayden IR</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ms. Renee Bouche</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mr. Cameron Donahue</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">661-723-7723</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">651-653-1854</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">renee@simulations-plus.com</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">cameron@haydenir.com</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 1, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Lisa
LaVange, PhD, Appointed to Board of Directors of Simulations Plus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Brings 35+ Years of Industry and Regulatory
Expertise to Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lancaster, CA, May 1, 2019 &ndash; </B>Simulations
Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical
discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company&rsquo;s Board of Directors. With
a distinguished career spanning more than 35 years, Dr. LaVange brings expertise in biostatistics and experience with academia,
commercial organizations, including Quintiles, the largest pharmaceutical outsourcing services company in the U.S., and government
regulators, including a senior position at the U.S. Food and Drug Administration (FDA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. LaVange currently serves as Professor
and Associate Chair of the Department of Biostatistics in the Gillings School of Global Public Health at the University of North
Carolina at Chapel Hill. At UNC, she directs the establishment of a new Master's in Public Health (MPH) program with a concentration
in data science, and is planning a regulatory science curriculum focused on statistical methodologies in two areas: precision medicine
and real-world evidence. In addition, she is currently Principal Investigator (PI) of the coordinating centers for two large and
complex trial networks: the NICHD-sponsored Adolescent Medicine Trials in HIV/AIDS Interventions Network (ATN) and the NHLBI-sponsored
Precision Medicine in Severe and Exacerbation-Prone Asthma Network (PreciSE).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From 2011 to 2017, Dr. LaVange served as
Director of the Office of Biostatistics in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration
(FDA). In this role, she directed 215 statistical reviewers, analysts, and support staff involved in the development and application
of statistical methodology for drug regulation. She was responsible for statistical review of all investigational drugs, therapeutic
biologics, biosimilar products, and generic drugs. She also chaired the Statistical Policy Council and was a member of CDER's Medical
Policy Council, setting statistical policy and overseeing statistical guidance development and publication for the Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Previously, she worked for six years at
Quintiles, Inc. (now IQVIA), serving as Vice President of Biostatistics for her last three years. Quintiles is the largest pharmaceutical
outsourcing services company in the U.S. In this role, she directed over 200 statisticians and programmers located in five offices
across North America, supporting clinical trial operations, regulatory submissions, and post-marketing evaluations for a variety
of large and small pharmaceutical and biotechnology companies. Dr. LaVange also served as Vice President, Biostatistics and Data
Management, for Inspire Pharmaceuticals, Inc. Dr. LaVange is an elected fellow of the American Statistical Association (ASA) and
was the 2018 ASA President. She is also former president of the Eastern North American Region of the International Biometric Society
(ENAR-IBS) and former IBS Board member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;For more than 35 years, I have worked
with commercial organizations, academic researchers, and government regulators in areas of statistical research and methodologies,
with a particular focus on biotechnology,&rdquo; commented Dr. LaVange. &ldquo;Throughout most of that time, Simulations Plus has
been a leader in the advancement of sophisticated modeling and simulation technology in this sector. I am honored and excited to
join the Board of Directors, and I look forward to helping Simulations Plus continue its growth. Technology continues to play an
increasingly vital role in drug development, and I hope to accelerate adoption of <I>in silico</I> modeling as a member of the
Simulations Plus Board of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Walt Woltosz, Founder and Chairman of the
Board, added: &ldquo;Dr. LaVange was selected after the most exhaustive search for a new independent director in our company&rsquo;s
history, and we could not be more thrilled to add a leader with her broad and noteworthy expertise to our board. Her tenures at
Quintiles and Inspire provide highly relevant experience to our board, enabling her to easily put herself in the position of our
customers. In addition, the Board and management will benefit from her experience with the FDA, as well as her deep academic background.
Concurrently, Dr. Ted Grasela has resigned from the Board. He remains Cognigen President and will continue to focus on the growth
of our consulting practice and his work with key clients and the FDA. We thank Ted for his outstanding service to the Board of
Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shawn O&rsquo;Connor, Chief Executive Officer
of Simulations Plus, added: &ldquo;Dr. LaVange adds highly relevant experience across all facets of our industry to an already
strong Board of Directors. Our entire management team looks forward to benefitting from her experience and expertise.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. LaVange will serve as an independent
director, with a term through the 2020 annual shareholder meeting. It is anticipated that Dr. LaVange will serve as the Chairman
of the Compensation Committee and also will be a member of the nominating and audit committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting
services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney
injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge
and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed
to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and
regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry,
pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically
based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company,
and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Follow us on Twitter | LinkedIn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Z 1@# 2(  A$! Q$!_\0
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M/RJM^U;<?&?]I72?"%DOPIUOPUX=:]9ULV1KFZ,F GGW&U0(442,%5N3\YZ
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MD([#83E5)&1S0![517GF@_'CPCXAU#PS81SZEI]]XDDO(M+M=6TB[L);A[9
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
